Skip to main content

– Bring unprecedented medical experience by strengthening partnerships with pharmaceutical companies in Japan and the United States to build a medical data platform –

TOKYO and SINGAPORE, August 22, 2022 /PRNewswire/ — Ubie, Inc., a healthcare AI startup with a mission to “develop a guide to healthcare for everyone,” announced that it has raised $26.2 million (*1) in the 1st round of Series C funding. New investors in the round include Norinchukin Capital Co., Ltd., NVenture Capital Limited (wholly owned subsidiary of NEC Capital Solutions Limited), The Dai-ichi Life Insurance Company , Limited and Egg FORWARD, Inc., while existing investors include SUZUKEN CO., LTD. To date, Ubie has raised $59.8 million (*2).

Ubie is one of the few startups in the world to have a medical data platform in direct contact with patients and medical institutions. Ubie offers two services that focus on the “medical questionnaire” as a gateway to healthcare, using AI as the core technology.

The “AI-powered Symptom Checker” provided to patients asks about 20 questions about their symptoms to discover associated diseases and provide more detailed and actionable health information. Since its launch, it has been trusted by 5 million monthly users worldwide, including in Japan and the United States

Ubie offers “AI-powered Patient Intake”, a service that streamlines the medical interview process for medical facilities. This service relies on a database of approximately 50,000 medical articles from around the world, created by more than 50 active physicians. The service has been introduced to more than 1,000 medical facilities worldwide and continues to improve the operational efficiency of these facilities.

Ubie will aim to bring a new medical experience to Japan and the United States by connecting patients, medical institutions and pharmaceutical companies through the medical data platform it is building to solve the following medical problems;
– ensuring that patients go to the right medical facility at the right time,
– to ensure that physicians can access relevant and up-to-date knowledge from the large amount of the latest information on diseases and rare diseases that are not their specialty, and,
– ensure that pharmaceutical companies continue to provide patients with appropriate information and scientific findings related to their condition.

Series C funding will be used to fuel business growth in Japan and the United States to build a medical data platform that connects patients, medical institutions and pharmaceutical companies.

Ubie Co-founder and CEO Yoshinori AbeMD, said: “Not only in Japan, but also in other countries, the current healthcare system suffers from various losses due to the fragmentation of information held by patients, medical institutions and pharmaceutical companies. This fundraiser aims to accelerate collaboration with pharmaceutical companies and create an unprecedented consumer-centric medical experience using Ubie’s data platform. Ubie is already in business with more than 20 major pharmaceutical companies in Japan and other countries, which brings Ubie one step closer to achieving its mission “Developing a healthcare guide for all”, both in Japan and the United States”

(*1) $26.2 million = 3.5 billion yen (from August 12, 2022)
(*2) $59.8 million = 7.98 billion yen (as above)

About Ubie

Ubie is a Japanese healthcare technology startup founded by a doctor and an engineer in 2017. Using AI as its core technology, the company develops and delivers an AI-powered patient questionnaire that guides patients from symptoms to care appropriate medical devices and improves operational efficiency in the medical field. Ubie promotes the creation of a society in which everyone can access the medical care that best suits them.

For more information, please visit:
AI-powered symptom checker:
(Japanese version: )

SOURCEUbie, Inc.